The company's acoustic pulmonary imaging system suits Chinese cultural norms.
Deep Breeze Medical Diagnosis Ltd. has obtained certification from China State Food and Drug Administration (SFDA) for the company's acoustic pulmonary imaging system. The approval comes a few months after the US Food and Drug Administration (FDA) approved the system.
Deep Breeze has sales in the US, Europe, Japan, South Korea, Singapore, and Australia. The Chinese approval is significant both because of China's large population and because of the suitability of the company's product to Chinese cultural norms.
Deep Breeze founder, president and CEO Dr. Igal Kushnir said, "The Chinese are heavy smokers and have a very high rate of pulmonary diseases. Culturally, breathing is very significant in traditional Chinese medicine, and also has a place of honor among conventional doctors. Chinese medicine is an interesting combination of the two medical schools."
Published by Globes [online], Israel business news - www.globes-online.com - on March 11, 2008
© Copyright of Globes Publisher Itonut (1983) Ltd. 2008